Dr. Hoogwerf is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8972 Huntington Pointe Dr
Sarasota, FL 34238Phone+1 317-292-6387- Is this information wrong?
Summary
- I am a retired endocrinologist whose career has included 30 years in academic clinical settings (University of MN and the Cleveland Clinic) focused on patient care and clinical trials in diabetes and cardiovascular disease. I then spent 8 1/2 years at Eli Lilly in the Diabetes Business unit working in diabetes drug development. I have set up a personal consulting company called "High Doc Consulting" with a focus on drug development and medical writing.
Education & Training
- University of MinnesotaFellowship, Endocrinology, Diabetes, and Metabolism, 1978 - 1981
- Hennepin HealthcareResidency, Internal Medicine, 1976 - 1978
- Hennepin HealthcareInternship, Transitional Year, 1971 - 1972
- University of Minnesota Medical SchoolClass of 1971
- Calvin College Health CenterBA, Biology/Chemistry, 1967
Certifications & Licensure
- FL State Medical License 2018 - 2025
- OH State Medical License 1985 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Laureate Award American College of Physicians, Ohio Chapter, 2005
- Endocrinology Teacher of the Year 2005
- Laureate Teacher Cleveland Clinic Foundation, 2005
- Join now to see all
Publications & Presentations
PubMed
- 405 citationsExenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyJohn B. Buse, Michael A. Nauck, Thomas Forst, Wayne Huey-Herng Sheu, Sylvia K. Shenouda
Lancet. 2013-01-12 - 409 citationsUse of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.John B. Buse, Richard M. Bergenstal, Leonard C. Glass, Cory R. Heilmann, Michelle S. Lewis
Annals of Internal Medicine. 2011-01-18 - 1185 citationsEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.rosiglitazone Medication Trial Investigators, Hertzel C. Gerstein, Salim Yusuf, Jackie Bosch, Janice Pogue
Lancet. 2006-09-23
Journal Articles
- Risk Factors for 30-Day Readmission Following Hypoglycemia-Related Emergency Room and Inpatient AdmissionsEmons MF, Bae JP, Hoogwerf BJ, Kindermann SL, Taylor RJ, Nathanson BH, BMJ Open Diab Res Care, 1/1/2016
- Major Adverse Cardiovascular Events with Basal Insulin Peglispro versus Comparator Insulins in Patients with Type 1 or Type 2 Diabetes: a meta-analysisHoogwerf BJ, Lincoff AM, Rodriguez A, Chen L, Qu Y., Cardiovascular Diabetology., 1/1/2016
- Perspectives on some controversies in cardiovascular disease risk assessment in the pharmaceutical development of glucose lowering medicationsHoogwerf, BJ, Manner, DH, Fu, H, Moscarelli, E, Gaydos, BL, Heine, R, Diabetes Care, 1/1/2016
- Join now to see all
Books/Book Chapters
Authored Content
- GLP-1 RAs: Beyond Glycemic Control to Cardiovascular, Renal, and Liver BenefitsJuly 2024
- The Continuing Saga of Genes, Pathophysiology and Diabetes MellitusJune 2022
- Research Updates from ADA 2021July 2021
- Diabetes Mellitus: What’s New in the Diabetes LandscapeJune 2020
- Diabetes Mellitus: What’s New in the Diabetes LandscapeJune 2020
- Join now to see all
Press Mentions
- Another Study Ties Statins to T2D: Should Practice Change?November 4th, 2023
Professional Memberships
- Member
- Member
- Member
Hospital Affiliations
- MyMichigan Medical Center MidlandMidland, Michigan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: